Top Markets
Coin of the day
Impact Therap-b Impact Therap-b

Impact Therap-b

7630
Rank in Stocks #13207
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and... IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.
Share Price
$1.85
Market Cap
$510.85M
Change (1 day)
-7.37%
Change (1 year)
-
Country
CN
Trade Impact Therap-b (7630)

Category

Dividend yield history for Impact Therap-b (7630)
Impact Therap-b (stock symbol: 7630) dividend yield (TTM) as of 2026: 0
Average dividend yield, last 5 years : 0.00%
Dividend yield history for Impact Therap-b (7630) from 2026 to 2026
Dividend Yield at the end of each year (TTM)
Year Dividend Yield Change
Not enough data for the provided dates.
Dividend yields (TTM) for similar companies or competitors
Company Dividend Yield Country
0.57%
US
2.01%
US
2.74%
US
2.69%
CH
2.47%
US